TSHA
Companies
NASDAQ
Taysha Gene Therapies Inc.
Health Care
$2.37
Price Chart
Overview
About TSHA
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Market Cap
$738.7M
Volume
10.4M
Avg. Volume
7.2M
P/E Ratio
-6.4285717
Dividend Yield
0.00%
Employees
74.0
Company Information
Risk & Correlation Analysis
Market Correlation
N/A
N/A
Volatility
N/A
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, TSHA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$738.7M
Volume10.4M
P/E Ratio-6.43
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 15, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025